Bio-Techne

Yahoo Finance • 19 days ago

No. 20 North Carolina holds off Georgia Tech in ACC opener

Seth Trimble scored a team-high 19 points, helping lead No. 20 North Carolina to a 68-65 win over visiting Georgia Tech in the Atlantic Coast Conference opener for both teams in Chapel Hill, N.C. on Saturday.... Full story

Yahoo Finance • last month

TikTok parent ByteDance’s valuation hits $300 billion amid US ban uncertainty, WSJ reports

TikTok's Chinese parent company ByteDance is valuing itself at about $300 billion after a recent buyback offer, the Wall Street Journal reported on Saturday, even as the tech giant's popular TikTok app faces the prospect of a looming ban i... Full story

Yahoo Finance • 3 months ago

ScaleReady announces a G-Rex® Grant has been awarded to renowned cancer immunologist Dr. Christopher A. Klebanoff

ST. PAUL, Minn., Oct. 7, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher A. Klebanoff, MD, a physician-scientist at M... Full story

Yahoo Finance • 3 months ago

BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT

MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initia... Full story

Yahoo Finance • 3 months ago

ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape

ST. PAUL, Minn., Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T th... Full story

Yahoo Finance • 3 months ago

Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant

PHILADELPHIA, Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant... Full story

Yahoo Finance • 3 months ago

ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics

ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Th... Full story

Yahoo Finance • 3 months ago

ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies

ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-... Full story

Yahoo Finance • 4 months ago

Some May Be Optimistic About Bio-Techne's (NASDAQ:TECH) Earnings

Soft earnings didn't appear to concern Bio-Techne Corporation's (NASDAQ:TECH) shareholders over the last week. Our analysis suggests that while the profits are soft, the foundations of the business are strong. Check out our latest analysi... Full story

Yahoo Finance • 4 months ago

Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations

Bio-Techne (NASDAQ:TECH) Full Year 2024 Results Key Financial Results Revenue: US$1.16b (up 2.0% from FY 2023). Net income: US$168.1m (down 41% from FY 2023). Profit margin: 14% (down from 25% in FY 2023). The decrease in margin was driv... Full story

Yahoo Finance • 5 months ago

BIO-TECHNE DECLARES DIVIDEND

MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be paya... Full story

Yahoo Finance • 5 months ago

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS

MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased b... Full story

Yahoo Finance • 11 months ago

SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex™ SYSTEM

MINNEAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) had the honor of welcoming presentations from leading scientists from two major biopharmaceutical companies, Pfizer and Sanofi, at the WCBP conference held in... Full story

Yahoo Finance • last year

BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY

MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, An... Full story

Yahoo Finance • last year

LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS

MINNEAPOLIS, Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project.... Full story

Yahoo Finance • last year

Should You Hold Bio-Techne Corporation (TECH) For the Long Term?

Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000... Full story

Yahoo Finance • last year

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Key Insights Bio-Techne's estimated fair value is US$57.87 based on 2 Stage Free Cash Flow to Equity With US$63.58 share price, Bio-Techne appears to be trading close to its estimated fair value The US$77.69 analyst price target for TECH... Full story

Yahoo Finance • last year

ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE

Kitted assays for clinical laboratories streamline the detection of challenging genes and variants to improve results for underrepresented populations MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today a... Full story

Yahoo Finance • last year

Bio-Techne (NASDAQ:TECH) sheds 6.6% this week, as yearly returns fall more in line with earnings growth

Bio-Techne Corporation (NASDAQ:TECH) shareholders might be concerned after seeing the share price drop 26% in the last quarter. But at least the stock is up over the last five years. However we are not very impressed because the share pric... Full story

Yahoo Finance • last year

Various Headwinds Pressured Bio-Techne Corporation (TECH) Shares in Q3

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. The fund declined 6.05% (Institutional Shares) in the quarter compared to a... Full story